Elevance Health (ELV) News Today

Capital International Inc. CA boosted its position in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 9.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,592 shares of the company's s

Molina Healthcare's Q2 earnings and strategic acquisitions fuel a surge in its stock price, signaling the potential for continued growth.

Lake Street Advisors Group LLC boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 61.5% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,247 shares of the company's stock after purchasing an additional

Elevance Health, Inc. (NYSE:ELV - Get Free Report) CEO Gail Boudreaux sold 34,000 shares of the business's stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the transaction, the chief executive officer now owns 126,709 shares in the company, valued at $63,478,674.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cantor Fitzgerald reiterated an "overweight" rating and issued a $600.00 price objective on shares of Elevance Health in a report on Tuesday.

Elevance Health, Inc. (NYSE:ELV - Get Free Report) Director Robert L. Dixon, Jr. sold 305 shares of the company's stock in a transaction on Friday, July 19th. The shares were sold at an average price of $506.76, for a total value of $154,561.80. Following the transaction, the director now directly owns 9,721 shares in the company, valued at approximately $4,926,213.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ontario Teachers Pension Plan Board trimmed its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 28.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,833 shares of the com

Elevance Health, Inc. (NYSE:ELV - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for Elevance Health in a research report issued on Wednesday, July 17th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings of $3

Acadian Asset Management LLC trimmed its holdings in Elevance Health, Inc. (NYSE:ELV - Free Report) by 40.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,453 shares of the company's stock after selling 22,218

M&G Plc bought a new position in Elevance Health, Inc. (NYSE:ELV - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 391,886 shares of the company's stock, valued at approximately $203,389,000. Elevance Health comprises approximately 1.2% of M

Barden Capital Management Inc. reduced its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 58.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,128 shares of the company's stock aft

TD Cowen lowered their target price on Elevance Health from $624.00 to $589.00 and set a "buy" rating for the company in a report on Friday.

Hims & Hers Health leverages telehealth's accessibility to disrupt traditional healthcare and deliver personalized wellness solutions.

Elevance Health, Inc. (NYSE:ELV - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2024 earnings per share (EPS) estimates for shares of Elevance Health in a note issued to investors on Wednesday, July 17th. Leerink Partnrs analyst W. Mayo now forecasts that the company wil

TD Asset Management Inc lowered its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 3.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 267,061 shares of the co

Barclays reduced their target price on Elevance Health from $621.00 to $611.00 and set an "overweight" rating for the company in a research note on Thursday.

Elevance Health (NYSE:ELV) Sees Strong Trading Volume on Better-Than-Expected Earnings

Bank of America restated a "neutral" rating and issued a $530.00 price target (down previously from $646.00) on shares of Elevance Health in a report on Thursday.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 49.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 166,095 shares of the company's stock after sellin